FLT3tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations

Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies.

(2017) M. Talpaz et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD

(2013) C. C. Smith et al.   BLOOD

Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy

(2013) M. Pratcorona et al.   BLOOD

Potent Graft-versus-Leukemia Effect after Reduced-Intensity Allogeneic SCT for Intermediate-Risk AML with FLT3-ITD or Wild-Type NPM1 and CEBPA without FLT3-ITD

(2012) Gaëlle Labouré et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers

(2012) S M Sengsayadeth et al.   BONE MARROW TRANSPLANTATION

Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation

(2012) Elisabeth Zirm et al.   BRITISH JOURNAL OF HAEMATOLOGY

Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia

(2012) Gautam Borthakur et al.   CANCER

The Origin and Evolution of Mutations in Acute Myeloid Leukemia

(2012) John S. Welch et al.   CELL

Diversity of the juxtamembrane and TKD1 mutations (Exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data

(2012) Susanne Schnittger et al.   GENES CHROMOSOMES & CANCER

Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis

(2012) Salut Brunet et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors

(2012) A B Williams et al.   LEUKEMIA

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

(2012) R M Stone et al.   LEUKEMIA

Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors

(2012) E Weisberg et al.   LEUKEMIA

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses

(2012) S K Metzelder et al.   LEUKEMIA

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

(2012) Catherine C. Smith et al.   NATURE

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

(2012) Li Ding et al.   NATURE

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

(2012) Jay P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Role of Allogeneic Transplantation for FLT3/ITD Acute Myeloid Leukemia: Outcomes from 133 Consecutive Newly Diagnosed Patients from a Single Institution

(2011) Amy E. DeZern et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation with Sorafenib

(2011) Manish Sharma et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

(2011) T. Sato et al.   BLOOD

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

(2011) M. Levis et al.   BLOOD

Molecular remission of FLT3-ITD+ positive AML relapse after allo-SCT by acute GVHD in addition to sorafenib

(2011) W H Krüger et al.   BONE MARROW TRANSPLANTATION

Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors

(2011) A. Parmar et al.   CANCER RESEARCH

Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications

(2011) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia

(2011) S Schnittger et al.   LEUKEMIA

FLT3 as a therapeutic target in AML: still challenging after all these years

(2010) T. Kindler et al.   BLOOD

Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

(2010) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

(2010) Thomas Fischer et al.   JOURNAL OF CLINICAL ONCOLOGY

A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias

(2010) K W Pratz et al.   LEUKEMIA

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML

(2009) K. W. Pratz et al.   BLOOD

Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome

(2009) S. Kayser et al.   BLOOD

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

(2009) P. P. Zarrinkar et al.   BLOOD

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

(2009) S. Metzelder et al.   BLOOD

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML

(2009) F. Breitenbuecher et al.   BLOOD

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML

(2009) J. Zhou et al.   BLOOD

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

(2009) Thomas O'Hare et al.   CANCER CELL

FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro

(2009) N. von Bubnoff et al.   CANCER RESEARCH

Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome

(2009) Elaine R. Mardis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structural and numerical variation of FLT3/ITD in pediatric AML

(2008) S. Meshinchi et al.   BLOOD

Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor

(2008) F. Breitenbuecher et al.   BLOOD

Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia

(2008) Weiguo Zhang et al.   JNCI-Journal of the National Cancer Institute

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Richard F. Schlenk et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting FLT3 for the Treatment of Leukemia

(2008) Donald Small   SEMINARS IN HEMATOLOGY